US 11,951,185 B2
RNA constructs and uses thereof
Ugur Sahin, Mainz (DE); Gábor Boros, Mainz (DE); Azita Josefine Mahiny, Mainz (DE); Jonas Reinholz, Mainz (DE); and Katalin Karikó, Rydal, PA (US)
Assigned to BioNTech SE, Mainz (DE)
Filed by BioNTech SE, Mainz (DE)
Filed on Dec. 30, 2021, as Appl. No. 17/565,921.
Application 17/565,921 is a continuation of application No. PCT/EP2021/060508, filed on Apr. 22, 2021.
Claims priority of application No. PCT/EP2020/061239 (WO), filed on Apr. 22, 2020; application No. PCT/EP2020/066968 (WO), filed on Jun. 18, 2020; application No. PCT/EP2020/068174 (WO), filed on Jun. 26, 2020; application No. PCT/EP2020/069805 (WO), filed on Jul. 13, 2020; application No. PCT/EP2020/071733 (WO), filed on Jul. 31, 2020; application No. PCT/EP2020/071839 (WO), filed on Aug. 3, 2020; application No. PCT/EP2020/073668 (WO), filed on Aug. 24, 2020; application No. PCT/EP2020/081544 (WO), filed on Nov. 9, 2020; application No. PCT/EP2020/081981 (WO), filed on Nov. 12, 2020; application No. PCT/EP2020/082601 (WO), filed on Nov. 18, 2020; application No. PCT/EP2020/082989 (WO), filed on Nov. 20, 2020; application No. PCT/EP2020/083435 (WO), filed on Nov. 25, 2020; application No. PCT/EP2020/084342 (WO), filed on Dec. 2, 2020; application No. PCT/EP2020/085145 (WO), filed on Dec. 8, 2020; application No. PCT/EP2020/085653 (WO), filed on Dec. 10, 2020; application No. PCT/EP2020/087844 (WO), filed on Dec. 23, 2020; application No. PCT/EP2021/050027 (WO), filed on Jan. 4, 2021; application No. PCT/EP2021/050874 (WO), filed on Jan. 15, 2021; application No. PCT/EP2021/050875 (WO), filed on Jan. 15, 2021; application No. PCT/EP2021/051772 (WO), filed on Jan. 26, 2021; application No. PCT/EP2021/052572 (WO), filed on Feb. 3, 2021; application No. PCT/EP2021/052716 (WO), filed on Feb. 4, 2021; application No. PCT/EP2021/054622 (WO), filed on Feb. 24, 2021; and application No. PCT/EP2021/059947 (WO), filed on Apr. 16, 2021.
Prior Publication US 2022/0273820 A1, Sep. 1, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 48/00 (2006.01); A61K 9/00 (2006.01); A61K 9/127 (2006.01); A61K 9/51 (2006.01); A61K 31/7088 (2006.01); A61K 31/7105 (2006.01); A61K 31/711 (2006.01); A61K 31/7115 (2006.01); A61K 31/712 (2006.01); A61K 39/00 (2006.01); A61K 39/12 (2006.01); A61K 39/215 (2006.01); A61P 31/14 (2006.01); A61P 35/00 (2006.01); B82Y 5/00 (2011.01); C12N 7/00 (2006.01); C12N 15/11 (2006.01); C12N 15/67 (2006.01); C12N 15/88 (2006.01); C12P 19/34 (2006.01); A61K 38/00 (2006.01)
CPC A61K 48/0066 (2013.01) [A61K 9/0019 (2013.01); A61K 9/1271 (2013.01); A61K 9/5123 (2013.01); A61K 9/5146 (2013.01); A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 31/711 (2013.01); A61K 31/7115 (2013.01); A61K 31/712 (2013.01); A61K 39/0011 (2013.01); A61K 39/12 (2013.01); A61K 39/215 (2013.01); A61K 48/0033 (2013.01); A61P 31/14 (2018.01); A61P 35/00 (2018.01); B82Y 5/00 (2013.01); C12N 7/00 (2013.01); C12N 15/11 (2013.01); C12N 15/67 (2013.01); C12N 15/88 (2013.01); C12P 19/34 (2013.01); A61K 38/00 (2013.01); A61K 2039/53 (2013.01); A61K 2039/54 (2013.01); A61K 2039/545 (2013.01); A61K 2039/55555 (2013.01); C12N 2770/18022 (2013.01); C12N 2770/18034 (2013.01); C12N 2770/18071 (2013.01); C12N 2770/20034 (2013.01); C12N 2840/00 (2013.01)] 49 Claims
 
1. A composition or medical preparation comprising an RNA polynucleotide comprising a sequence encoding a payload, wherein:
the RNA polynucleotide optionally comprises a modified uridine in place of one or more uridines; and
the 5′ terminus of the RNA polynucleotide comprises m7(3′OMeG)(5′)ppp(5′)(2′OMeA1)pG2pA3pA4pN5, wherein N5 is uridine or a modified uridine.